Bevacizumab Biosimilar – Research Grade: HRP

Bevacizumab Biosimilar – Research Grade

Horse Radish Peroxidase (HRP)

VEGF

n/a

IgG1

Receptor tyrosine-protein kinase erbB-2, MLN 19, HER2, HER2/neu

CHO Cells

Human

Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Our Bevacizumab biosimilar is for research use only (RUO).

Bevacizumab is a humanized IgG1 monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Bevacizumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).

0.5 mg/ml

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 – 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase).

This HRP conjugate is stable when stored at 2-8°C. Do not freeze.

Flow Cytometry, ELISA

Each investigator should determine their own optimal working dilution for specific applications.